BioNTech vs Viatris
BioNTech (BNTX), health care, and Viatris (VTRS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Viatris is worth $23.4B on the stock market and BioNTech $21B: Viatris is valued at 11% more. BioNTech's operating margin in its latest fiscal year was -49.0% and Viatris's -18.6%. Over the past year BioNTech's share price has moved -16.8% and Viatris's +93.7%.
Key facts
- BioNTech market value
- $21B
- Viatris market value
- $23.4B
- BioNTech revenue
- $3.2BFY to 2025-12-31
- Viatris revenue
- $14.3BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | BioNTech | Viatris |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $21Blower | $23.4Bhigher |
| Revenue | $3.2Blower | $14.3Bhigher |
| Earnings | -$1.3Bhigher | -$3.5Blower |
| Employees | 7,807lower | 30,000higher |
| Total assets | $24.4Blower | $37.2Bhigher |
| Valuation | ||
| P/E | — | — |
| P/S | 6.6higher | 1.6lower |
| P/B | — | 1.7 |
| Dividend yield | — | 2.31% |
| Profitability | ||
| Operating margin | -49.0%lower | -18.6%higher |
| Balance sheet | ||
| Net assets | $21.3Bhigher | $14.7Blower |
| Total liabilities | $3.1Blower | $22.5Bhigher |
| Total debt | — | $14.4B |
| Cash on hand | $8.5Bhigher | $1.3Blower |
| Price change | ||
| Today | -0.47%higher | -1.40%lower |
| 1 year | -16.8%lower | +93.7%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
BioNTech only (4)
- Temasek0.3%
- Primecap team0.2%
- Dodge & Cox team0.2%
- Julian and Felix Baker0.1%
Viatris only (9)
- Christopher Davis5.5%
- Anthony Bozza3.2%
- Larry Robbins3.1%
- Bill Miller (founder)2.8%
- Harry Burn2.5%
- David Einhorn1.1%
- Louis Bacon0.3%
- Josef Lakonishok0.3%
- Joel Greenblatt0.2%
Percentages are each holding's share of that investor's reported portfolio. Who owns BNTX · Who owns VTRS
More on BioNTech
Further comparisons
BioNTech against its closest peers
Viatris against its closest peers
Learn
Questions and answers
Which is bigger, BioNTech or Viatris?
By market value, Viatris is the larger: $23.4B against $21B for BioNTech. By revenue in its latest fiscal year, Viatris is the larger: $14.3B against $3.2B for BioNTech.
Which has the higher operating margin?
Viatris: -18.6%, against -49.0% for BioNTech. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both BioNTech and Viatris?
None of the tracked superinvestors holds both in their latest 13F filing. 4 hold BioNTech and 9 hold Viatris.
Cite this page
Funkfolio, “BioNTech vs Viatris”, data as of 18 November 2026. https://funkfolio.com/compare/bntx-vs-vtrs
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.